Sofinnova opens biotech creation ‘toolbox’ as part of Europe-wide strategy
Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at setting up and accelerating biotech startups across Europe.
Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at setting up and accelerating biotech startups across Europe.
The FDA is creating a new advisory committee made up of nine voting members who will provide insight into potential treatments for genetic metabolic diseases.
Merck & Co. was the talk of the town in Madrid after signing a multi-billion dollar antibody drug conjugate (ADC) deal with Daiichi Sankyo to open this year’s European Society for Medical Oncology annual meeting.
North Carolina-based CRO Catawba Research has linked up with electronic medical records miner Elligo Health Research to expand patient access to its clinical trials.
Venture capitalists and biotech CEOs have been largely speaking with one voice this year with respect to the state of new financing, underscoring that the only thing that matters is having enough money to last until the next catalyst.
The Federal Trade Commission (FTC) has scuttled Sanofi’s licensing deal with Maze Therapeutics. With the FTC moving to block the deal, the Big Pharma is pulling out rather than working through the antitrust maze that has sprung up between it and the asset.
Bristol Myers Squibb has filled the antibody-drug conjugate (ADC) shaped hole in its pipeline by following the increasingly well-trodden path to China, handing SystImmune $800 million upfront for a phase 2 solid tumor candidate as part of a deal worth up to $8.4 billion.
It looked for a while like AstraZeneca was planning to back out of the vaccines business for good, but the acquisition of respiratory syncytial virus (RSV) shot developer Icosavax suggests the British Big Pharma plans to be a player for a while longer.
Affimed is slashing the list of opportunities open to its bispecific innate cell engager AFM24. The failure of data in multiple tumor types to clear its bar for continuation drove the biotech to narrow its focus to lung cancer—but there are signs of encouragement in that setting and for lead candidate AFM13.
The medical device trade association AdvaMed has selected the new chair of its board of directors, tapping GE HealthCare’s president and CEO, Peter Arduini.